By Sabela Ojea

 

Reckitt Benckiser Group PLC said Friday it is proposing to sell its E45 skincare brand and related sub-brands to Karo Pharma AB for an implied enterprise value of 200 million pounds ($268.2 million).

The consumer-goods company--which houses Dettol, Harpic and Durex among its brands--said E45 generated a combined net revenue of GBP43 million for the year ended Dec. 31, 2020.

"The proposed sale, if completed, would be another step forward in Reckitt's plan to actively manage its portfolio for higher growth," the London-listed company said.

The transaction is expected to be completed in the first quarter of 2022, it said.

 

Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix

 

(END) Dow Jones Newswires

December 24, 2021 02:31 ET (07:31 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Reckitt Benckiser (LSE:RKT)
Historical Stock Chart
From Apr 2022 to May 2022 Click Here for more Reckitt Benckiser Charts.
Reckitt Benckiser (LSE:RKT)
Historical Stock Chart
From May 2021 to May 2022 Click Here for more Reckitt Benckiser Charts.